Return to News Categories

ALL NEWS SECTIONS:
MOST POPULAR SECTIONS:
Cattle - Hogs / Livestock News Currencies News Energy News Grain News Index News Interest Futures News Metals Futures News Reports: Crops, CFTC, etc Soft Commodities News

Futures and Commodity Market News

Agreement Reached for ESSA Pharma to Acquire Realm Therapeutics

VANCOUVER and HOUSTON, May 16, 2019 (Canada NewsWire via COMTEX) --

Acquisition Expected to be Completed by Mid-Year 2019

ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ: EPIX; TSX-V: EPI) announced today that it has entered into a definitive agreement with Realm Therapeutics plc ("Realm") (NASDAQ: RLM) setting forth the terms of an acquisition ("Acquisition") whereby ESSA will acquire all of the issued and outstanding shares of Realm in an all-stock transaction. The Acquisition, subject inter alia to Realm Shareholder approval, is intended to be implemented by means of a United Kingdom ("UK") Court-sanctioned scheme of arrangement under Part 26 of the UK Companies Act 2006 and is expected to be completed by mid-year 2019. Upon the closing of the Acquisition, the Company will continue to operate as ESSA Pharma Inc., trade on the Nasdaq Capital Market and TSX-V Market and operate in the United States as ESSA Pharmaceuticals Corp., a Houston, TX-registered wholly-owned subsidiary. The Company will focus on advancing ESSA's pipeline of novel potential treatments for prostate and other cancers.

The terms of the Acquisition value Realm's issued and outstanding shares at approximately USD $21.5 million, which represents a 5% premium over Realm's estimated net cash amount of USD $20.5 million at the closing of the Acquisition. Under the terms of the Acquisition, Realm Shareholders will be entitled to receive approximately 0.058 ESSA ordinary shares for each Realm Share based upon a 60-day volume-weighted average price of ESSA shares of USD $3.19 per share of ESSA as of the close of trading on May 14(th), 2019, subject to a final adjustment based on Realm's final net cash amount prior to closing of the Acquisition. Upon the close of the Acquisition, ESSA's current management team will continue to lead the Company. In addition, it is expected that the Company's Board of Directors will be increased to nine members of which three will be Realm-nominated candidates, with two current ESSA directors resigning.

"We are truly excited by the opportunity afforded by this transaction to further advance ESSA's aniten program of N-terminal domain inhibitors of the androgen receptor," said Dr. David R. Parkinson, Chief Executive Officer of ESSA. "Our lead candidate EPI-7386 was recently nominated as the IND candidate for the treatment of prostate cancer. We believe that the current transaction, which is intended to be supplemented by an equity financing involving insiders and other investors, will deliver sufficient financial resources to ESSA to achieve multiple value-inflection points and key near-term objectives in the coming two years including: first, completion of a Phase 1 clinical trial for our lead program EPI-7386 in patients with advanced prostate cancer progressing on the latest generation of anti-androgens; secondly, generation of proof-of-concept clinical data from a Phase 1 trial for EPI-7386 in combination with those same anti-androgens in prostate cancer patients; and thirdly, further advance our early preclinical pipeline of novel anitens for the potential treatment of breast cancer."

"We are very pleased to enter into this transaction with ESSA, whose lead program is a first-in-class therapy for the treatment of castration-resistant prostate cancer, which represents a significant unmet need for patients," said Alex Martin, Chief Executive Officer of Realm. "Following a comprehensive review of strategic alternatives, Realm's Board of Directors concluded that the proposed acquisition will provide an opportunity to create meaningful value and, as such we have significant support from our shareholders for the transaction."

This Announcement is neither an offer to sell nor a solicitation of an offer to buy any securities and shall not constitute an offer, solicitation, or sale in any jurisdiction in which such offer, solicitation, or sale is unlawful. Any securities offered or sold in the United States pursuant to any financing must be either registered under the U.S. Securities Act or offered or sold pursuant an applicable exemption from such registration requirements.

Oppenheimer & Co. Inc. is acting as a financial advisor to ESSA and has delivered a fairness opinion to its Board of Directors. Eversheds Sutherland (International) LLP, Blake Cassels & Graydon LLP, and Skadden, Arps, Slate, Meagher & Flom LLP are acting as UK, Canadian, and US legal counsel, respectively, to ESSA. MTS Health Partners is acting as a financial advisor to Realm. Cooley LLP is acting as US and UK legal counsel and Fasken Martineau DuMoulin LLP is acting as legal counsel to Realm.Acquisition Details

The Acquisition is intended to be implemented by means of a UK Court-sanctioned scheme of arrangement under Part 26 of the Companies Act. The Acquisition is conditional on, among other things: (i) the approval of Realm Shareholders at the Court Meeting and the passing of the resolutions by Realm Shareholders at the General Meeting; and (ii) the sanction of the Scheme by the UK Court. The Acquisition does not require the approval of ESSA Shareholders.

The Acquisition is expected to become Effective by mid-year 2019, subject to the satisfaction (or, where applicable, waiver) of the Conditions set out in Appendix I to this Announcement.

Further details of the Acquisition will be contained in the Scheme Document which is intended to be posted to Realm Shareholders along with notices of the Court Meeting and General Meeting and the Forms of Proxy within 15 Business Days following the date of this Announcement, unless Realm and ESSA otherwise agree to a later date.

Biotechnology Value Fund ("BVF") and certain affiliated funds are shareholders of both ESSA and Realm and will be receiving New ESSA Shares upon closing of the Acquisition. The issuance of the New Essa Shares to BVF pursuant to the Acquisition constitutes a related-party transaction under Canadian Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The foregoing transaction is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 pursuant to section 5.7(1)(c) of MI 61-101 and the exemption under 5.5(e) as the Acquisition is supported by Clarus Ventures LLC (Clarus), an arm's length control person of ESSA.

This summary should be read in conjunction with, and is subject to, the full text of this Announcement (including its Appendices).

The Acquisition will be subject to the Conditions and further terms that are set out in Appendix I, and to the full terms and conditions which will be set out in the Scheme Document. Appendix II contains the bases and sources of certain information used in this Announcement. Appendix III contains details of the irrevocable undertakings received in relation to the Acquisition. Appendix IV contains definitions of terms used in this Announcement.

About ESSA Pharma Inc.ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR-driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently progressing IND-enabling studies and expects to enter clinical studies with EPI-7386 in the first calendar quarter of 2020. For more information about ESSA, please visit www.essapharma.com or follow us on Twitter.

About Prostate CancerProstate cancer is the second-most commonly diagnosed cancer among men and the fifth most common cause of male cancer death worldwide (Globocan, 2018). Adenocarcinoma of the prostate is dependent on androgen for tumor progression and depleting or blocking androgen action has been a mainstay of hormonal treatment for over six decades. Although tumors are often initially sensitive to medical or surgical therapies that decrease levels of testosterone, disease progression despite castrate levels of testosterone generally represents a transition to the lethal variant of the disease, metastatic CPRC ("mCRPC"), and most patients ultimately succumb to the illness. The treatment of mCRPC patients has evolved rapidly over the past five years. Despite these advances, additional treatment options are needed to improve clinical outcomes in patients, particularly those who fail existing treatments including abiraterone or enzalutamide, or those who have contraindications to receive those drugs. Over time, patients with mCRPC generally experience continued disease progression, worsening pain, leading to substantial morbidity and limited survival rates. In both in vitro and in vivo animal studies, ESSA's novel approach to blocking the androgen pathway has been shown to be effective in blocking tumor growth when current therapies are no longer effective.

About Realm TherapeuticsRealm Therapeutics has been engaged in a strategic review. The Investing Policy, which has guided the strategic review by the Directors, requires the Company to seek to invest in, partner with, acquire and/or be acquired by a company with meaningful development potential in the life sciences sector or with good overall business prospects. For more information on Realm Therapeutics, please visit www.realmtx.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

IMPORTANT NOTES

The City Code on Takeovers and MergersThe City Code on Takeovers and Mergers does not apply to the Acquisition.

Further information

This Announcement is for information purposes only and is not intended to and does not constitute, or form any part of, an offer to sell or an invitation to purchase or subscribe for any securities or the solicitation of any vote or approval in any jurisdiction pursuant to the Acquisition or otherwise. The Acquisition will be made solely by the Scheme Document, which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. INVESTORS ARE ADVISED TO READ THE SCHEME DOCUMENT, AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, WHEN IT BECOMES AVAILABLE CAREFULLY AND IN ITS ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO THE ACQUISITION BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors may obtain a free copy of the Scheme Document (when available) at the Securities and Exchange Commission's website at www.sec.gov, or free of charge from Realm at www.realmtx.com or by directing a request to Realm at ir@realmtx.com. Any voting decision or response in relation to the Acquisition should be made solely on the basis of the Scheme Document.

This Announcement does not constitute a prospectus or a prospectus equivalent document.

Overseas Realm shareholders

The release, publication or distribution of this Announcement in jurisdictions other than the United Kingdom, Canada and the United States may be restricted by law and therefore any persons who are subject to the laws of any jurisdiction other than the United Kingdom, Canada or the United States (including Restricted Jurisdictions) should inform themselves about, and observe, any applicable legal or regulatory requirements. In particular, the ability of persons who are not resident in the United Kingdom, Canada or the United States or who are subject to the laws of another jurisdiction to vote their Scheme Shares in respect of the Scheme at the Court Meeting, or to execute and deliver Forms of Proxy appointing another to vote at the Court Meeting on their behalf, may be affected by the laws of the relevant jurisdictions in which they are located or to which they are subject. Any failure to comply with applicable legal or regulatory requirements of any jurisdiction may constitute a violation of securities laws in that jurisdiction. This Announcement has been prepared for the purpose of complying with English, Canadian and U.S. law and the information disclosed may not be the same as that which would have been disclosed if this Announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom, Canada and the United States.

Copies of this Announcement and any formal documentation relating to the Acquisition are not being, and must not be, directly or indirectly, mailed or otherwise forwarded, distributed or sent in or into or from any Restricted Jurisdiction or any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction and persons receiving such documents (including custodians, nominees and trustees) must not mail or otherwise forward, distribute or send them in or into or from any Restricted Jurisdiction. Doing so may render invalid any related purported vote in respect of the Acquisition.

The availability of the New ESSA Shares under the Acquisition to Realm Shareholders who are not resident in the United Kingdom may be affected by the laws of the relevant jurisdictions in which they are resident (including affecting the ability of such Realm Shareholders to vote their Realm Shares with respect to the Scheme and the Acquisition at the Realm Shareholder Meetings, or to execute and deliver Forms of Proxy appointing another to vote at the Realm Shareholder Meetings on their behalf). Persons who are not resident in the United Kingdom or who are subject to the laws and/or regulations of another jurisdiction should inform themselves of, and should observe, any applicable requirements. Further details in relation to Overseas Shareholders are contained in the Scheme Document.

Notice to U.S. investors in Realm

The Acquisition relates to the acquisition of shares of an English company and is proposed to be effected by means of a scheme of arrangement under English law. An Acquisition effected by means of a scheme of arrangement is not subject to any proxy solicitation or tender offer rules under the U.S. Exchange Act. Accordingly, the Scheme is subject to the disclosure requirements, rules and practices applicable in the United Kingdom to schemes of arrangement, which differ from the requirements of U.S. proxy solicitation or tender offer rules.

The New ESSA Shares to be issued under the Scheme have not been registered under the U.S. Securities Act, or with any securities regulatory authority or under the securities laws of any state or other jurisdiction of the United States. Accordingly, the New ESSA Shares may not be offered, sold, resold, delivered, distributed or otherwise transferred, directly or indirectly, in or into the United States absent registration under the US Securities Act or an exemption therefrom. The New ESSA Shares are expected to be issued in the United States in reliance upon the exemption from the registration requirements of the U.S. Securities Act provided by Section 3(a)(10) thereof.

For the purposes of qualifying for the exemption from the registration requirements of the U.S. Securities Act afforded by Section 3(a)(10) thereunder, Realm will advise the Court through counsel that it will rely on the Section 3(a)(10) exemption based on the Court's sanctioning of the Scheme following a hearing on the fairness of the terms and conditions of the Scheme to Realm Shareholders, at which hearing all such shareholders are entitled to attend in person or through counsel to support or oppose the sanctioning of the Scheme and with respect to which notification has been given to all such shareholders.

The New ESSA Shares generally should not be treated as "restricted securities" within the meaning of Rule 144(a)(3) under the U.S. Securities Act and persons who receive securities under the Scheme (other than persons who are "affiliates" of Realm or ESSA prior to the Effective Date or of ESSA after the Effective Date) may resell them without restriction under the U.S. Securities Act.

It may be difficult for US Realm Shareholders to enforce their rights and claims arising out of the U.S. federal securities laws, since ESSA and Realm are located in countries other than the United States, and some or all of their officers and directors may be residents of countries other than the United States. U.S. Realm Shareholders may not be able to sue a non-U.S. company or its officers or directors in a non-U.S. court for violations of US securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment.

None of the securities referred to in this Announcement has been approved or disapproved by the U.S. Securities and Exchange Commission, any state securities commission in the United States or any other U.S. regulatory authority, nor have such authorities passed upon or determined the adequacy or accuracy of the information contained in this Announcement. Any representation to the contrary is a criminal offence in the United States.

U.S. Realm Shareholders and Realm ADS Holders also should be aware that the Acquisition contemplated herein may have tax consequences to them in the United States. U.S. Realm Shareholders and Realm ADS Holders are urged to consult with legal, tax and financial advisers in connection with making a decision regarding this Acquisition.

Warning Concerning Forward-Looking Statements

All statements included in this Announcement, other than statements or characterisations of historical fact, are forward-looking statements within the meaning of the federal securities laws, including Section 21E of the U.S. Exchange Act or forward-looking information within the meaning of applicable Canadian securities laws and other securities laws and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Whenever the document uses words such as, without limitation, "believe," "expect," "anticipate," "intend," "plan," "estimate," "will," "may," "predict," "could," "seek," "forecast" and negatives or derivatives of these or similar expressions, they are making forward-looking statements. Examples of such forward-looking statements include, but are not limited to, references to the anticipated benefits of the Acquisition and the expected time of effectiveness of the Acquisition; expectations as to the concurrent financing and timing thereof; statements concerning future drug development plans and projected timelines for the initiation and completion of preclinical and clinical trials; the potential for the results of ongoing preclinical or clinical trials and the efficacy of the drug candidates of Realm or ESSA; the potential market opportunities and value of drug candidates; other statements regarding future product development and regulatory strategies, including with respect to specific indications; any statements regarding the future financial performance, results of operations or sufficiency of capital resources to fund its operating requirements; and any other statements that are not statements of historical fact. These forward-looking statements are based upon ESSA's present intent, beliefs or expectations, but forward-looking statements are not guaranteed to occur and may not occur.

Investors are cautioned that any forward-looking statements are not guarantees of future performance and may involve significant risks and uncertainties, and that actual results may vary materially from those expressed or implied by the forward-looking statements. Important risk factors that may cause ESSA's actual results to differ materially from their forward-looking statements include, but are not limited to: (1) the Acquisition is subject to the satisfaction or waiver of certain conditions, including the receipt of requisite approvals by Realm Shareholders, and the sanction of the Scheme by the Court, which conditions may not be satisfied or waived; (2) uncertainties as to the timing of the consummation of the Acquisition and the ability of each party to consummate the Acquisition; (3) the risk that the Acquisition disrupts the parties' current operations or affects their ability to retain or recruit key employees; (4) the possible diversion of management time on Acquisition-related issues; (5) potential litigation relating to the Acquisition; (6) unexpected costs, charges or expenses resulting from the Acquisition; (7) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Acquisition; (8) substantial capital in the future to fund its operations and research and development; (9) ESSA's ability to continue to fund and successfully progress internal research and development efforts and to create effective, commercially-viable drugs; and (10) the fact that ESSA's compounds may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere.

Forward-looking information is developed based on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 20-F dated December 13, 2018 under the heading "Risk Factors", a copy of which is available on ESSA's profile on the SEDAR website at www.sedar.com, ESSA's profile on EDGAR at www.sec.gov, and as otherwise disclosed from time to time on ESSA's SEDAR profile at www.sedar.com.

You should not place undue reliance upon forward looking statements. Except as required by law, ESSA does not intend to update or change any forward looking statements as a result of new information, future events or otherwise.

RECOMMENDED ACQUISITION

OF

REALM THERAPEUTICS PLC ("REALM")

BY

ESSA PHARMA INC. ("ESSA")

(to be implemented by way of a scheme of arrangement under Part 26 of the Companies Act 2006)

1. Introduction

Realm and ESSA have announced that the boards of directors of Realm and ESSA have reached agreement on the terms of a recommended acquisition whereby the entire issued share capital of Realm will be acquired by ESSA. It is intended that the Acquisition will be implemented by means of a Court-sanctioned scheme of arrangement under Part 26 of the Companies Act.

2. The Acquisition

Under the Acquisition, which is subject to the Conditions and further terms set out in Appendix I to this Announcement, Realm Shareholders on the register of members at the Scheme Record Time will be entitled to receive a fraction of a New ESSA Share for every 1 Realm Share held (the "Exchange Ratio").

The Exchange Ratio will be calculated on the basis of Realm's Net Cash Amount as at the Effective Date which will be set out in a statement to be prepared by Realm and agreed between Realm and ESSA (or, if Realm and ESSA do not agree, subject to expert determination in accordance with the procedure set out in the Implementation Agreement) prior to the Court Hearing.

Subject to the provisos set out below, the number of New ESSA Shares to be issued to Scheme Shareholders shall be an amount equal to 105% of Realm's Net Cash Amount divided by US$3.189, being the volume-weighted average price of the ESSA Shares on Nasdaq for the 60 trading days prior to entry into the Implementation Agreement. The Exchange Ratio shall be determined by dividing the resulting number of New ESSA Shares by 116,561,917, being the number of Realm Shares currently in issue.

The calculation of the number of New ESSA Shares and the Exchange Ratio is subject to the following:

    --  Realm and ESSA have agreed that the maximum number of New ESSA
        Shares that can be issued as consideration pursuant to the
        Scheme is 7,933,301 New ESSA Shares.
    --  In addition, if Realm's Net Cash Amount is less than
        US$19,500,000, and ESSA elects to waive the condition that the
        Net Cash Amount will be at least US$19,500,000 on the Effective
        Date set out in paragraph B of Appendix I and proceed with the
        sanction of the Scheme, there will be no downwards adjustment
        and the number of New ESSA Shares and the Exchange Ratio shall
        be calculated on the basis that the Net Cash Amount is
        US$19,500,000.


By way of illustration, if Realm's Net Cash Amount is US$20,500,000 (which is the estimated Net Cash Amount) the number of New ESSA Shares to be issued would be 6,749,608 and the Exchange Ratio would be 0.05791 of a New ESSA Share for each 1 Realm Share subject to the Scheme. In addition:

    --  The minimum number of New ESSA Shares that could be issued
        under the Scheme would be 6,420,359 and the maximum number of
        New ESSA Shares that could be issued under the Scheme would be
        7,933,301.
    --  The Exchange Ratio would be within a range of 0.055081 of a New
        ESSA Share for every 1 Realm Share (if Realm's Net Cash Amount
        is US$19,500,000 (or below US$19,500,000 and ESSA elects to
        waive the condition set out in paragraph B of Appendix I) and
        0.068061 of a New ESSA Share for every 1 Realm Share if the
        maximum number of New ESSA Shares are to be issued under the
        Scheme.


The final Exchange Ratio will be applied to the holding of each Realm Shareholder after the date of the Court Hearing at 6:00 p.m. on the Business Day immediately prior to the Scheme becoming Effective with the resulting number of New ESSA Shares being rounded down to the nearest whole number.

3. Background to and reasons for the Acquisition

Following the results of two clinical trials and the resulting decision to suspend further clinical development of all programmes, in September 2018 Realm announced the commencement of a process to explore strategic alternatives for Realm, which might have included, without limitation, the sale of some or substantially all of its assets, a sale of stock, a strategic merger or other business combination transaction or other transaction between Realm and a third party. Realm retained MTS Health Partners, L.P. to serve as an advisor to the Realm Board in certain aspects of the process.

On 15 February 2019, Realm announced that it had agreed to sell certain assets, which comprised its Vashe® wound care royalty stream, hypochlorous acid ("HOCl") related equipment, intellectual property (including know-how, patents and copyrights), program records, and certain assigned contracts and intellectual property licenses to Urgo North America for gross proceeds of US$10 million. Realm then further announced its intention to delist its ordinary shares from admission to trading on AIM and adopt an Investing Policy.

The disposal, AIM delisting and Investing Policy adoption were approved by shareholders at the general meeting held on 15 March 2019. The AIM delisting was effective on 27 March 2019 and the asset disposal completed on 28 March 2019.

The Investing Policy requires the Realm Directors to examine potential strategic opportunities. The Investing Policy, which remains the strategic focus of the Realm Directors, requires Realm to seek to invest in, partner with, acquire and/or be acquired by companies with meaningful development potential in the life sciences sector or with good overall business prospects; or, if a suitable transaction is not identified, the Realm Group will consider winding down and distributing the remaining assets to shareholders, following satisfaction of applicable obligations.

As such, Realm has been undertaking a strategic review process, focused on identifying potential strategic acquisitions.

The Realm Board now considers that the Acquisition is in the best interests of the Realm Shareholders.

4. Recommendation

For the reasons set out in this Announcement, the Realm Directors, who consulted with MTS Health Partners, L.P. as to the financial terms of the Acquisition, consider such terms to be fair and reasonable. In evaluating the financial terms of the Acquisition, the Realm Directors have taken into account publicly available information compiled by MTS Health Partners, L.P. regarding the financial position and public market valuation of ESSA and the public market valuation of other companies in similar stages of development as ESSA with a focus on oncology.

Accordingly, the Realm Directors believe that the terms of the Acquisition, including the terms of the Implementation Agreement, are fair and reasonable and that proceeding with the Acquisition is in the best interests of the Realm Shareholders and unanimously recommend that Realm Shareholders vote in favour of the Scheme at the Court Meeting and the Resolutions to be proposed at the General Meeting, as Charles Spicer, Alex Martin and Marella Thorell (being those Realm Directors who hold Realm Shares) have irrevocably undertaken to do in respect of their own holdings of, in aggregate, 572,045 Realm Shares (representing approximately 0.49 per cent. of the issued ordinary share capital of Realm on 15 May 2019 (being the last practicable date prior to the publication of this Announcement)).

5. Background to and reasons for the Realm Board's recommendation

In the course of making the determination that the Implementation Agreement, the Acquisition and the other transactions contemplated by the Implementation Agreement are fair and reasonable and are in the best interests of the Realm Shareholders, and to recommend that Realm's Shareholders vote in favour of the Scheme at the Court Meeting and the Resolutions to be proposed at the General Meeting, the Realm Board considered numerous reasons, including the following material reasons for and benefits of the Acquisition: the availability and attractiveness of strategic alternatives, the future prospects of ESSA, the views of major shareholders, the robust negotiation process, the likelihood of completion, the terms of the Implementation Agreement and the irrevocable undertakings received in respect of the Acquisition.

6. Irrevocable undertakings

ESSA has received Irrevocable Undertakings to vote or procure votes in favour of the resolutions relating to the Scheme at the Meetings from Charles Spicer, Alex Martin and Marella Thorell, each a Realm Director, in respect of their entire beneficial holdings, amounting to 572,045 Realm Shares representing approximately 0.49 per cent. of the issued ordinary share capital of Realm on 15 May 2019 (being the last practicable date prior to the publication of this Announcement).

In addition to the irrevocable undertakings to vote or procure votes in favour of the resolution that ESSA has obtained from certain Realm Directors, ESSA has also received irrevocable undertakings from BVF Partners LP, OrbiMed Private Investments VI, LP, Oracle Management Limited and Sussex Trading Company Limited, each Realm Shareholders, to vote or procure votes in favour of the resolutions relating to the Scheme at the Meetings in respect of their entire beneficial holdings, amounting to 52,418,451 Realm Shares, in aggregate, representing approximately 44.97 per cent. of the issued ordinary share capital of Realm as at 15 May 2019 (being the last practicable date prior to the publication of this Announcement).

Further details of these Irrevocable Undertakings are set out in Appendix III.

7. Information on ESSA

ESSA is a public company incorporated in British Columbia, Canada and operates in the United States through its wholly-owned subsidiary, ESSA Pharmaceuticals Corp., based in Houston, Texas. ESSA is a pharmaceutical company currently in preclinical stage focused on developing novel and proprietary therapies for the treatment of prostate cancer in patients whose disease is progressing despite treatment with current therapies, including abiraterone and enzalutamide. ESSA believes its clinical series of compounds can significantly expand the interval of time in which patients suffering from castration-resistant prostate cancer ("CRPC") can benefit from hormone-based therapies. Specifically, the compounds act by disrupting the androgen receptor ("AR") signalling pathway, the primary pathway that drives prostate cancer growth, by preventing AR activation through selective binding to the Tau-5 region of the N-terminal domain ("NTD") of the AR. In this respect, ESSA's compounds differ from classical anti-androgens, which interfere either with androgen synthesis, or with the binding of androgens to the ligand-binding domain ("LBD"), located at the opposite end of the receptor. A functional NTD is essential for activation of the AR; blocking the NTD inhibits AR-driven transcription and therefore androgen-driven biology. We believe that the transcription inhibition mechanism of ESSA's preclinical series of compounds is unique, and has the advantage of bypassing identified mechanisms of resistance to the anti-androgens currently used in the treatment of CRPC. ESSA has been granted by the United States Adopted Names ("USAN") Council a unique USAN stem "-aniten" to recognize this new mechanistic class. ESSA refers to this series of proprietary compounds, currently in development, as the "Aniten" series. In preclinical studies, blocking the NTD has demonstrated the capability to prevent AR-drive gene expression. A recently completed Phase I clinical trial of ESSA's first generation ralaniten acetate ("EPI-506") demonstrated prostate-specific antigen ("PSA") declines, a sign of inhibition of AR-drive biology, at higher does levels.

The British Columbia Cancer Agency ("BCCA") and the University of British Columbia ("UBC") are joint owners of the intellectual property that constitutes ESSA's initial series of compounds, which include EPI-002 and EPI-506. ESSA licensed the original EPI-family of drugs from UBC and the BCCA. ESSA is party to a license agreement with the BCCA and UBC dated 22 December 2010, as amended, which provides ESSA with exclusive world-wide rights to the issued patents and patent applications in respect of EPI-series compounds, including the next generation Aniten compounds. ESSA believes that it has developed a strong and defensive intellectual property position for multiple EPI and Aniten structural classes, with 14 active patent families, covering different structural motifs/analogues. Patent applications are pending in the United States and in contracting states to the Patent Cooperation Treaty for the Aniten next-generation NTD inhibitors, with expiry between 2037-2039.

ESSA's shares are traded on the Nasdaq Capital Market under the symbol "EPIX", and on the TSXV under the symbol "EPI". ESSA's principal executive offices are located at Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5 and its telephone number is +1 (778) 331-0962.

For more information about ESSA, please visit www.essapharma.com.

8. Information on Realm

Realm is a public limited company incorporated in England and Wales. Realm had been focused on the development of novel, prescription treatments for immune mediated diseases in adults and children. In 2018, the Realm Group completed two Phase 2 clinical studies. In March 2018, the Realm Group reported that its Phase 2 study of PR013, a topical ophthalmic solution for the treatment of Allergic Conjunctivitis, did not demonstrate efficacy. As a result, Realm discontinued further development of that program. In September 2018, the Realm Group announced top-line results of its Phase 2 trial of PR022 in Atopic Dermatitis which did not meet the Realm Group's threshold for continued investment and, as such, Realm decided to discontinue all drug development programs based on its proprietary technology. Also in September 2018, the Realm Group announced the hiring of MTS Health Partners, L.P., to act as an advisor in relation to a strategic review that was initiated by the Board to explore options which include the potential sale of the Realm Group as a possible outcome.

On 15 February 2019, Realm announced that it had agreed to sell certain assets, which comprised its Vashe® wound care royalty stream, hypochlorous acid ("HOCl") related equipment, intellectual property (including know-how, patents and copyrights), program records, and certain assigned contracts and intellectual property licenses to Urgo North America for gross proceeds of US$10 million. Realm then further announced its intention to delist its ordinary shares from admission to trading on AIM and adopt an Investing Policy.

The disposal, AIM delisting and Investing Policy adoption were approved by shareholders at the general meeting held on 15 March 2019. The AIM delisting was effective on 27 March 2019 and the asset disposal completed on 28 March 2019.

The Investing Policy requires the Realm Directors to examine potential strategic opportunities. The Investing Policy, which remains the strategic focus of the Realm Directors, requires Realm to seek to invest in, partner with, acquire and/or be acquired by companies with meaningful development potential in the life sciences sector or with good overall business prospects; or, if a suitable transaction is not identified, the Realm Group will consider winding down and distributing the remaining assets to shareholders, following satisfaction of applicable obligations.

As such, Realm has been in the midst of a strategic review process, focused on identifying potential strategic transactions.

The Realm ADSs are traded on Nasdaq under the symbol "RLM." Realm's principal executive offices are located at 267 Great Valley Parkway, Malvern, PA 19355, USA, and its telephone number is +1 484 321 2700.

For more information about Realm, please visit www.realmtx.com.

9. Financing

The entirety of the Consideration payable to Scheme Shareholders will be satisfied by the issue of New ESSA Shares and as such there will be no cash element.

10. Acquisition related arrangements

Implementation Agreement

Explanatory Note Regarding the Implementation Agreement

The following is a summary of the material provisions of the Implementation Agreement, a copy of which will be available at www.realmtx.com and under ESSA's profile on www.sedar.com. This summary does not purport to be complete and may not contain all of the information about the Implementation Agreement that may be important to shareholders. You should carefully read the Implementation Agreement in its entirety, as the rights and obligations of the parties thereto are governed by the express terms of the Implementation Agreement and not by this summary or any other information contained in this document.

The following summary of the Implementation Agreement is intended to provide information regarding the terms of the Implementation Agreement and is not intended to provide any factual information about Realm or modify or supplement any factual disclosures about Realm in its public reports filed with the SEC. In particular, the Implementation Agreement and the related summary are not intended to be, and should not be relied upon as, disclosures regarding any facts and circumstances relating to Realm. The representations and warranties contained in the Implementation Agreement were made only for purposes of that agreement and as at specific dates, were solely for the benefit of the parties to the Implementation Agreement, may be subject to a contractual standard of materiality different from what might be viewed as material to shareholders and may be subject to limitations agreed upon by the parties, including being qualified by confidential disclosures made by the parties to each other. You should not rely on the representations and warranties contained in the Implementation Agreement as characterisations of the actual state of facts or condition of Realm, ESSA or any of their respective subsidiaries, affiliates or businesses. In addition, information concerning the subject matter of the representations, warranties and covenants may change, which subsequent information may or may not be fully reflected in Realm's or ESSA's respective public disclosures.

Structure of the Acquisition

The Acquisition will be implemented by means of a scheme of arrangement under Part 26 of the Companies Act 2006. The Scheme involves an application by Realm to the Court to sanction the Scheme, pursuant to which all of the Realm Scheme Shares will be transferred to ESSA, in consideration for which holders of Realm Scheme Shares will receive the Consideration. The transfer of the Realm Scheme Shares to ESSA, provided for in the Scheme, will result in the entire issued share capital of Realm being held by ESSA.

When the Acquisition Becomes Effective

The Acquisition will become Effective once all the Conditions have been satisfied or (where applicable) waived, the Scheme has been sanctioned by the Court and a copy of the Court Order has been delivered to the Registrar of Companies.

Representations and Warranties

The Implementation Agreement contains representations and warranties of Realm, subject to certain exceptions in the Implementation Agreement and in the disclosure schedule delivered in connection with the Implementation Agreement as to, among other things: corporate existence and power; ownership of subsidiaries; corporate authority, consents and approvals relating to the execution, delivery and performance of the Implementation Agreement; capitalisation and indebtedness; SEC filings; financial statements; the absence of any changes, occurrences or developments that has had a material adverse effect with respect to Realm, the absence of certain material changes in the business of Realm since 31 December 2018; real property; compliance with laws and permits; regulatory matters; anti-corruption and bribery; tax matters; material contracts; environmental matters; insurance; employees and employee benefit plans; and privacy and data security.

The Implementation Agreement also contains broadly reciprocal representations and warranties of ESSA subject to certain exceptions in the Implementation Agreement and in the disclosure schedule delivered in connection with the Implementation Agreement.

Some of the representations and warranties in the Implementation Agreement are qualified by materiality qualifications or a "material adverse effect" qualification with respect to either Realm or ESSA, as discussed below.

For purposes of the Implementation Agreement, a "material adverse effect" with respect to either Realm or ESSA means, subject to certain exceptions described in the definition of "material adverse effect" in the Implementation Agreement, any state of facts, condition, development, circumstance, change, effect or event occurring on or after 15 May 2019 (being the date of the Implementation Agreement) which, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (i) the condition (financial or otherwise), business, assets, liabilities or results of operations of Realm or ESSA (as applicable) and its subsidiaries, taken as a whole, or (ii) the ability of Realm or ESSA (as applicable) to consummate the Acquisition on or before the Long Stop Date.

Conduct of Business Pending the Acquisition

The Implementation Agreement provides that, during the period from 15 May 2019, being the date of the Implementation Agreement, until the earlier of (a) the termination of the Implementation Agreement in accordance with its terms and (b) the Effective Date (the "relevant period"), except (i) as required or otherwise contemplated under the Implementation Agreement or as required by applicable law; (ii) with the written consent of ESSA (which will not be unreasonably withheld, conditioned or delayed); or (iii) as set forth in the disclosure schedule delivered in connection with the Implementation Agreement, Realm will, and will cause each of its subsidiaries to preserve intact its material assets (being its cash) and continue wind-down activities and maintain the listing of the Realm ADSs on Nasdaq (to the extent practicable and commercially reasonable).

In addition, during the relevant period, except (i) as required or otherwise contemplated under the Implementation Agreement or as required by applicable law; (ii) with the written consent of ESSA (which will not be unreasonably withheld, conditioned or delayed); or (iii) as set forth in the disclosure schedule delivered in connection with the Implementation Agreement, Realm will not, and will cause each of its subsidiaries not to, subject in each case to certain specified exceptions, among other things: authorise or pay any dividends; repurchase, redeem, issue or grant any Realm Shares or other equity interests; amend the Realm Articles; acquire any person or other business organisation; incur or guarantee any indebtedness; amend of modify its material contracts; commence any litigation; establish or adopt any benefit plan; grant or pay any termination payments or bonuses; hire any employees or contractors; enter into any collective bargaining agreement; adopt a plan or agreement of complete or partial liquidation; enter into any new line of business; sell any of its material assets; enter into any transaction with a Realm Shareholder; or make any changes in its accounting methods.

The Implementation Agreement also imposes similar restrictions on ESSA's conduct of business during the relevant period. In addition to those restrictions referred to in the paragraph above but applied in respect of ESSA's business, during this period, except (i) as required or otherwise contemplated under the Implementation Agreement or as required by applicable law; (ii) with the written consent of Realm (which consent shall not be unreasonably withheld, conditioned or delayed); or (iii) as set forth in the disclosure schedule delivered in connection with the Implementation Agreement, ESSA shall, and shall cause each of its subsidiaries to conduct their business in the ordinary course, preserve intact its material assets and business organisation and maintain its advantageous relationships with patients, material suppliers, material distributors and regulators.

For the relevant period, save in respect of certain employee share options or with the written consent of Realm (such consent not to be unreasonably withheld, conditioned or delayed) ESSA is also prevented from issuing, granting or selling or otherwise disposing of any additional shares of, or other equity interests in, ESSA or any of its subsidiaries, or securities convertible into or exchangeable for such shares or equity interests or issue or grant any options, warrants, calls, subscription rights or other rights of any kind to acquire such shares, other equity interests or securities, on terms which, when taken as a whole, can reasonably be considered to be more economically favourable to the person to whom such securities are to be issued than those on which the New ESSA Shares are to be issued under the Scheme.

Alternative Proposals; Non-solicitation

Except as expressly permitted by the Implementation Agreement, between 15 May 2019 and the earlier of the termination of the Implementation Agreement in accordance with its terms and the Effective Date, Realm and its subsidiaries will not, directly or indirectly, and will use their reasonable endeavours to cause their representatives not to:

    --  continue, and will procure the termination of, any
        solicitation, knowing encouragement, discussions or
        negotiations with any persons that may be ongoing with respect
        to an acquisition proposal (as defined below) and Realm
        confirmed that it has, (i) terminated access to any third party
        to any data room containing confidential information of Realm
        and (ii) requested the return or destruction of all
        confidential information provided to third parties prior to 15
        May 2019 that have, since 1 September 2018 entered into
        confidentiality agreements with Realm relating to a possible
        acquisition proposal;
    --  solicit, initiate or knowingly facilitate or encourage
        (including by way of furnishing non-public information) any
        inquiries regarding, or the making of any proposal or offer
        that constitutes, or could reasonably be expected to lead to,
        an acquisition proposal;
    --  engage in, continue or otherwise participate in any discussions
        or negotiations regarding, or furnish to any other person any
        non-public information in connection with, or for the purpose
        of soliciting or knowingly encouraging or facilitating, an
        acquisition proposal or any proposal or offer that could
        reasonably be expected to lead to an acquisition proposal;
    --  enter into any term sheet, letter of intent, implementation
        agreement, co-operation agreement, acquisition agreement,
        agreement in principle or similar agreement with respect to an
        acquisition proposal or any proposal or offer that could
        reasonably be expected to lead to an acquisition proposal; or
    --  waive or release any person from, forebear in the enforcement
        of, or amend any standstill agreement or any standstill
        provisions of any other contract.


Pursuant to the Implementation Agreement, and as used throughout this document, an "acquisition proposal" means any inquiry, proposal or offer from any person (other than ESSA) relating to (i) any direct or indirect acquisition or purchase, in a single transaction or a series of related transactions, of 25% or more (based on the fair market value thereof, as reasonably determined by the Realm Board) of the assets (including share capital of Realm's subsidiaries) of Realm and its subsidiaries, taken as a whole, or (B) shares carrying 25% or more of the aggregate voting power and economic rights of Realm or (ii) any takeover offer, exchange offer, merger, consolidation, business combination, recapitalisation, liquidation, dissolution, share exchange or similar transaction involving Realm that, if consummated, would result in any person (or the shareholders of any person) owning, directly or indirectly, shares carrying 25% or more of the aggregate voting power and economic rights of Realm or the resulting direct or indirect parent of Realm, other than, in each case, the Acquisition.

Receipt of Competing Acquisition Proposals

If at any time after 15 May 2019 and before the earlier of the termination of the Implementation Agreement in accordance with its terms and the Effective Date, Realm or any of its subsidiaries or any of their representatives receives an unsolicited bona fide written acquisition proposal from any person, which did not result from a breach of the non-solicitation provisions of the Implementation Agreement, then after providing notice to ESSA, Realm and its representatives may contact such person solely to clarify the terms and conditions thereof, and if the Realm Board determines in good faith, after consultation with its financial advisers and outside legal counsel, that such acquisition proposal constitutes or is reasonably likely to lead to a superior proposal (as defined below) and the failure to take such action would be in breach of their fiduciary duties or would violate their obligations under the Companies Act, then Realm and its representatives may:

    --  furnish, pursuant to an acceptable confidentiality agreement,
        information (including non-public information) with respect to
        Realm and its subsidiaries to the person who has made such
        acquisition proposal; provided that Realm will, as promptly as
        practicable (and in any event within 24 hours), provide to ESSA
        any non-public information concerning Realm and its
        subsidiaries that is provided to any person pursuant to this
        bullet point to the extent access to such information was not
        previously provided to ESSA or its representatives; and
    --  engage in or otherwise participate in discussions or
        negotiations with the person making such acquisition proposal
        for so long as Realm and its representatives reasonably believe
        it may lead to a superior proposal.


Pursuant to the Implementation Agreement, and as used throughout this document, a "superior proposal" means any bona fide written acquisition proposal that, if consummated, would result in a person (or the shareholders of any person) owning, directly or indirectly, (i) 80% or more of the aggregate voting power and economic rights of Realm or the resulting direct or indirect parent of Realm or (ii) all or substantially all of the assets (including share capital of Realm's subsidiaries) of Realm and its subsidiaries, taken as a whole, (A) on terms which the Realm Board determines, in good faith, after consultation with outside counsel and its financial adviser, would result in greater value to Realm Shareholders from a financial point of view than the Acquisition, including a price per Realm Share with a value greater than 10% above the Consideration, after taking into account all of the terms and conditions of such acquisition proposal and the Implementation Agreement and (B) that is reasonably likely to be completed relative to the Acquisition, taking into account all financial, regulatory, legal, timing and other aspects of such proposal.

Changes in Realm Board Recommendation

The Realm Board has unanimously recommended that Realm Shareholders vote in favour of the Scheme and the Resolutions, which recommendation is referred to as the "Realm Board Recommendation" in the Implementation Agreement. The Implementation Agreement permits the Realm Board to change its recommendation only in certain limited circumstances, as described below.

Except as expressly permitted by the Implementation Agreement, the Realm Board may not:

    --  withdraw (or modify in a manner adverse to ESSA), or publicly
        propose to withdraw (or modify in a manner adverse to ESSA),
        the Realm Board recommendation; or (ii) approve, recommend or
        declare advisable, or publicly propose to approve, recommend or
        declare advisable, any acquisition proposal (any action listed
        in this bullet point being a "Realm adverse change
        recommendation"); or
    --  approve, recommend or declare advisable, or propose to approve,
        recommend or declare advisable any contract with respect to any
        acquisition proposal, requiring, or reasonably expected to
        cause, Realm to delay or fail to consummate, or that would
        otherwise materially impede, interfere with or be inconsistent
        with, the Acquisition (other than an acceptable confidentiality
        agreement).


Notwithstanding anything to the contrary contained in the Implementation Agreement, at any time before the earlier of (i) the termination of the Implementation Agreement in accordance with its terms and (ii) the Effective Date, if Realm or any of its subsidiaries has received a bona fide written acquisition proposal, which did not result from a breach of the non-solicitation provisions of the Implementation Agreement from any person that has not been withdrawn, and after consultation with its financial advisers and outside legal counsel the Realm Board has determined, in good faith, that such acquisition proposal is a superior proposal, then:

    --  the Realm Board may make a Realm adverse change recommendation,
        and/or
    --  Realm may terminate the Implementation Agreement, and implement
        such superior proposal, in both cases, if and only if:
    --  Realm has given ESSA prior written notice of its intention to
        consider making a Realm adverse change recommendation or
        terminating the Implementation Agreement at least four Business
        Days prior to making any such Realm adverse change
        recommendation or termination, and ESSA has not elected during
        such notice period to negotiate in good faith with respect to
        any revisions to the terms of the Acquisition so that the
        revised terms proposed by ESSA are at least as favourable as
        the competing acquisition proposal; and
    --  Realm has provided to ESSA information with respect to such
        acquisition proposal in accordance with the terms of the
        Implementation Agreement; and after giving effect to the
        proposals made by ESSA during such period, if any, after
        consultation with financial advisers or outside legal counsel,
        the Realm Board has determined, in good faith, that such
        acquisition proposal is a superior proposal.


Each of the above bullet points will also apply to any material amendment to any acquisition proposal or any matching acquisition proposal made by ESSA and require written notice of Realm's intention to consider making a Realm adverse change recommendation or terminating the Implementation Agreement, except that the references to four Business Days will be three Business Days.

In the event that ESSA, in response to an acquisition proposal, proposes terms that are at least as favourable as the competing acquisition proposal, unless such competing party proposes a further superior proposal following ESSA's proposal, within four Business Days of ESSA's proposal, Realm will, and will procure its affiliates and representatives to, terminate all discussions with the other party.

Efforts to Complete the Acquisition

Realm and ESSA have agreed that prior to the Effective Date, Realm will use all reasonable endeavours to implement the Scheme in accordance with the terms of, and the timetable set out in, the Announcement and this document, and to consult with ESSA in relation to such implementation.

Subject to the terms and conditions of the Implementation Agreement, Realm and ESSA have agreed that each party to the Implementation Agreement will use all reasonable endeavours to: (i) make all filings (if any) and give all notices (if any) required to be made or given by such party pursuant to any material contract in connection with the Acquisition and (ii) seek any consent required to be obtained pursuant to any material contract by such party in connection with the Acquisition; and (iii) seek to lift any restraint, injunction or other legal bar to the Acquisition brought by any third person against such party.

ESSA has agreed to:

    --  provide promptly to Realm all such information about itself,
        ESSA Group and ESSA Directors as may reasonably be requested by
        Realm for the purpose of inclusion in the Scheme Document and
        to provide such other co-operation and assistance as may
        reasonably be required in connection with the preparation of
        the Scheme Document; and
    --  notify Realm promptly of: (i) any changes in the information
        disclosed in any document or announcement published by ESSA in
        connection with the Acquisition which are material in the
        context of that document or announcement; and (ii) any material
        new information which may be relevant to a Realm Shareholder in
        considering the merits of the Acquisition, and agrees that any
        such information may be published by Realm if (a) it determines
        that such disclosure is necESSAry to ensure that all Realm
        Shareholders have sufficient information to consider the merits
        of the Acquisition and (b) ESSA has consented to the content
        and form of the disclosure (such consent not to be unreasonably
        withheld, conditioned or delayed).


Realm has agreed to, among other things:

    --  prior to the General Meeting and Court Meeting, keep ESSA
        informed of the number of proxy votes received in respect of
        the Resolutions to be proposed at the General Meeting and the
        Court Meeting and promptly provide ESSA with details of any
        material changes to Realm's shareholder and other statutory
        registers which occur prior to the Effective Date; and
    --  provide, and procure that each member of the Realm Group
        provides, promptly to ESSA and its advisers such information,
        documentation and access to the management, employees,
        facilities and assets of the Realm Group and its advisers and
        independent auditors as is reasonably requested by ESSA for the
        purposes of implementing the Acquisition, post-Acquisition
        planning, verifying Realm's business plan and preparing or
        making any filing, notification or submission with a tax
        authority or governmental authority in connection with the
        Acquisition.


Other Covenants and Agreements

The Implementation Agreement also contains additional covenants, including, among others, covenants relating to the filing of this document; ESSA's right to seek injunctive or other equitable relief in relation to any breach or prospective breach of the undertakings described above in the following sections of this description of the Implementation Agreement: "Conduct of Business Pending the Acquisition," "Alternative Proposals; Non-solicitation," "Receipt of Realm Takeover Proposals," "Changes in Board Recommendation," and certain other covenants included in the Implementation Agreement; the delisting and deregistration of Realm Shares and Realm ADSs, and public announcements with respect to the Acquisition.

In addition, ESSA has given certain additional covenants in relation to certain securities law filings, resale registration statements, and confirmed its intention to use commercially reasonable efforts to (i) provide its shareholders with a PFIC Annual Information Statement and (ii) determine, on or before 1 March 2020, whether the Scheme qualified as a transaction described in Section 351 of the Code.

Conditions to Completion of the Acquisition

The Conditions to completion of the Acquisition are set out in Appendix I to this document. The Acquisition is conditional upon the Scheme becoming unconditional and becoming Effective, by no later than 11.59 p.m. on the Long Stop Date. The Scheme is conditional on:

    --  approval of the Scheme by Scheme Shareholders at the Court
        Meeting and at any separate class meeting which may be required
        by the Court or at any adjournment of any such meeting;
    --  the Court Meeting being held on or before the twenty-second day
        after the expected date of the Court Meeting as set out in the
        Scheme (or such later date, if any, as ESSA and Realm may agree
        and the Court may allow);
    --  approval of the Resolutions by Realm Shareholders at the
        General Meeting or any adjournment of that meeting;
    --  the General Meeting being held on or before the twenty-second
        day after the expected date of the General Meeting as set out
        in the Scheme (or such later date, if any, as ESSA and Realm
        may agree and the Court may allow);
    --  the sanction of the Scheme by the Court (with or subject to any
        modification, addition or condition which Realm and ESSA may
        agree and which the Court approves) and the delivery of a copy
        of the Court Order to the Registrar of Companies; and
    --  the Court Hearing being held on or before the date immediately
        preceding the Long Stop Date (or such later date, if any, as
        ESSA and Realm may agree and the Court may allow).
    --  In addition, ESSA and Realm have agreed that the Acquisition
        will be conditional upon the following Conditions and,
        accordingly, the necessary actions to make the Scheme Effective
        will not be taken unless the following Conditions have been
        satisfied or, where relevant, waived:
    --  on the Effective Date, Realm having a minimum Net Cash

Copyright (C) 2019 CNW Group. All rights reserved.

Please read the End User Agreement.
By accessing this page, you agree to the terms and conditions of the End User Agreement.

News provided by COMTEX.


Extreme Futures: Movers & Shakers

Hottest

Actives

Gainers

Today's Hottest Futures
Market Last Vol % Chg
Loading...

close_icon
open_icon